Interestingly, exploratory analyses found that canakinumab not only led to a dose-dependent reduction in HF hospitalizations and mortality[118], but targeted deep sequencing also revealed that subjects with TET2 CHIP had a greater response to canakinumab than those without it (62% vs. 7% reduction in MACE)[119]. This evidence concerns the gene TET2 and hydrops fetalis.